Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Current Liabilities (2016 - 2025)

Sangamo Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $42.5 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $42.5 million for Q4 2025, down 7.29% from a year ago — trailing twelve months through Dec 2025 was $42.5 million (down 7.29% YoY), and the annual figure for FY2025 was $42.5 million, down 7.29%.
  • Total Current Liabilities for Q4 2025 was $42.5 million at Sangamo Therapeutics, down from $50.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for SGMO hit a ceiling of $136.9 million in Q2 2021 and a floor of $39.0 million in Q2 2024.
  • Median Total Current Liabilities over the past 5 years was $52.0 million (2023), compared with a mean of $78.4 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 114.03% in 2021 and later plummeted 60.38% in 2023.
  • Sangamo Therapeutics' Total Current Liabilities stood at $127.9 million in 2021, then dropped by 12.65% to $111.7 million in 2022, then plummeted by 57.27% to $47.7 million in 2023, then fell by 4.04% to $45.8 million in 2024, then fell by 7.29% to $42.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $42.5 million (Q4 2025), $50.1 million (Q3 2025), and $47.7 million (Q2 2025) per Business Quant data.